Lucas Arruda

Company: CuraCell Holding AB

Job title: CSO

Bio:

Dr. Lucas Arruda is the Chief Scientific Officer at CuraCell, where he leads the development of CytoPLY and CC 38—an advanced platform and clinical-stage TIL product designed to treat late-stage, immunologically cold solid tumors. Under his scientific leadership, CuraCell has presented promising clinical data from named-patient programs at both AACR and ISCT, underscoring the therapeutic potential of TILs in patients unresponsive to conventional therapies.

Seminars:

Expanding TIL Therapies Beyond Melanoma: Overcoming Biological and Manufacturing Barriers 9:30 am

As TIL therapies move beyond melanoma into more complex tumor types, new biological and manufacturing challenges emerge. This session explores the interplay between tumor biology, starting material quality, and therapeutic end-points, highlighting strategies to enhance efficacy across diverse indications.Read more

day: Pre-Conference Workshop Day